DeepKinase

DeepKinase is a biotechnology company commercializing a PCT patented technology proteomics platform DoTK (Deep Omics of Tyrosine Kinase) to enable the next-generation precision medicines. Our vision is “turning cancer into a chronic disease”. Since establishment, DeepKinase has been committed to improving the survival rate and overall quality of life for cancer patients by identifying the most effective drugs tailored to the needs of individual patients, and committed to comprehensively supporting the development of new drugs in terms of target discovery, target identification, understanding mechanism of action, signalling network construction, drug repositioning, biomarker discovery, Drug combination and patient stratification etc. 嘉华药锐DeepKinase是一家数据驱动的磷酸化组学生物技术企业。以 “让癌症成为慢性病” 为愿景，用公司核心专利的功能蛋白质组学技术平台DoTK(Deep Omics of Tyrosine Kinase) ，能够清楚分析信号通路网络的活性全谱，从而帮助肿瘤患者快速找到最适用的药物，提高患者的生活水平和生活质量，降低耐药带来的患者肿瘤复发情况；并同步积累以患者信号通路网络活性和临床指征为核心的数据库，致力于从机制研究、靶点发现、靶点鉴定、药物重定位、生物标志物发现、药物联用等维度全面助力新药研发。